C.S. Latimer, J. Stair, J.C. Hincks, H.N. Currey, T.D. Bird, C.D. Keene, B.C. Kraemer, N.F. Liachko. 2022. TDP-43 promotes pathological tau phosphorylation and selective neurotoxicity. Disease Models and Mechanisms. Apr 1; 15(4).

R.L. Kow, A.H. Black, A.D. Saxton, N.F. Liachko, B.C. Kraemer. 2022. Loss of aly/ALYREF suppresses toxicity in both tau and TDP-43 models of neurodegeneration. GeroScience. Apr;44(2):747-761.

H.N. Currey, N.F. Liachko. 2021. Evaluation of motor impairment in C. elegans models of amyotrophic lateral sclerosis (ALS). Journal of Visualized Experiments. September 2; (175).

C.S. Latimer, N.F. Liachko. 2021. tau and TDP-43 synergy: a novel therapeutic target for sporadic late-onset Alzheimer’s disease (LOAD). GeroScience, Aug;43(4):1605-1614.

R.J. Eck, B.C. Kraemer, N.F. Liachko. 2021. Regulation of TDP-43 Phosphorylation in Aging and Disease. GeroScience. Aug;43(4):1627-1634.

P. McMillan^†, J. Wheeler^†, R.E. Gatlin, L. Taylor, T. Strovas, M. Baum, T.D. Bird, C. Latimer, C.D. Keene, B.C. Kraemer, N.F. Liachko. ^†Authors contributed equally. 2020. Adult onset pan-neuronal human Tau Tubulin Kinase 1 expression causes severe cerebellar neurodegeneration in mice reminiscent of human spinal cerebellar ataxia disorders. Acta Neuropathologica Communications. Nov 23;8(1):200.

E. Rojas, L. Martinez-Gonzalez, N.F. Liachko, C. Perez, B. Monti, B.C. Kraemer, D. I. Perez, A. Martin-Requero, C. Gil, A. Martinez. 2020. Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: a new therapeutic approach for amyotrophic lateral sclerosis. European Journal of Medicinal Chemistry. Oct 28:112968.

H.N. Currey, A. Melinkevich, P. Melquist, N.F. Liachko. 2020. ARENA-based activity profiling of tau and TDP-43 transgenic C. elegans. microPublication Biology. July 16;2020:10.17912.

J.M. Wheeler, P.J. McMillan, T.J. Strovas, N.F. Liachko, A. Amelie-Wolf, R.L. Klein, P. Szot, L. Robinson, H. Currey, C. Guthrie, M.A. Behlke, N.M. Kanaan, M. Raskind, E. Peskind, J.Q. Trojanowski, V.M.Y. Lee, L.-S. Wang, C.D. Keene, T.D. Bird, G.D. Schellenberg, B.C. Kraemer. 2019. The poly(A) binding protein MSUT2 controls resilience to both pathological tau and gliosis. Science Translational Medicine. Dec 18; 11(523).

N. F. Liachko^†, A. D. Saxton^†, P. J. McMillan, T. Strovas, C. D. Keene, T. D. Bird, B. C. Kraemer. ^†Authors contributed equally. 2019. Genome wide analysis reveals heparan sulfate epimerase modulates TDP-43 proteinopathy. PLoS Genetics. Dec 13;15(12).

M. Bartoletti^†, D. Bosco^†, S. Da Cruz^†, C. Lagier-Tourenne^†, N. Liachko^†, S. Markmiller^†, K. Webster, K. Wharton. ^†Authors contributed equally. 2019. Phenotypic suppression of ALS/FTD-associated neurodegeneration highlights mechanisms of dysfunction. J Neuroscience. 16 October; 39(42) 8217-8224.

S.M. Waldherr, T.A. Vadset, T.J. Strovas, N.F. Liachko, B.C. Kraemer. 2019. Constitutive XBP-1s-mediated activation of the endoplasmic reticulum unfolded protein response protects against pathological tau. Nature Communications. Sept 30;10(1):4443.

L.M. Taylor, P.J. McMillan, B.C. Kraemer, N.F. Liachko. 2019. Tau tubulin kinases in proteinopathy. FEBS Journal. Jul;286(13):2434-2446.

Latimer, C. S., Burke, B. T., Liachko, N. F., Currey, H. N., Kilgore, M. D., Gibbons, L. E., . . . Keene, C. D. (2019). Resistance and resilience to Alzheimer’s disease pathology are associated with reduced cortical pTau and absence of limbic-predominant age-related TDP-43 encephalopathy in a community-based cohort. Acta Neuropathologica Communications, 7(1). doi:10.1186/s40478-019-0743-1 [original work]

Taylor, L. M., Mcmillan, P. J., Kraemer, B. C., & Liachko, N. F. (2019). Tau tubulin kinases in proteinopathy. The FEBS Journal. doi:10.1111/febs.14866

Mitra, J., Guerrero, E. N., Hegde, P. M., Liachko, N. F., Wang, H., Vasquez, V., . . . Hegde, M. L. (2019). Motor neuron disease-associated loss of nuclear TDP-43 is linked to DNA double-strand break repair defects. Proceedings of the National Academy of Sciences, 116(10), 4696-4705. doi:10.1073/pnas.1818415116

Currey, H. N., & Liachko, N. F. A CRISPR/Cas9-generated cdc-7 loss of function mutation does not cause temperature-dependent fertility defects. MicroPublication Biology. https://doi.org/10.17912/MICROPUB.BIOLOGY.000085 [original work]

L .M. Taylor, P.J. McMillan, N.F. Liachko, T. Strovas, B. Ghetti, T.D. Bird, C.D. Keene, B.C. Kraemer. 2018. Pathological phosphorylation of tau and TDP-43 by TTBK1 and TTBK2 drives neurodegeneration. Molecular Neurodegeneration. Feb 6;13(1):7. [original work]

J.C. Weeks, C. Leasure, B.M. Suzuki, K.J. Robinson, W.M. Roberts, H. Currey, A.D. Saxton, T.D. Bird, B.C. Kraemer, J.M. Hawdon, C.R. Caffrey, N.F. Liachko. 2018. Sertraline, paroxetine, and chlorpromazine are rapidly acting anthelmintic drugs capable of clinical repurposing. Scientific Reports. Jan 17;8(1)975. [original work]

E.N. Guerrero, H. Wang, J. Mitra, P.M. Hegde, S.E. Stowell, N.F. Liachko, B.C. Kraemer, R.M. Garruto, K.S. Rao, M.L. Hegde. 2016. TDP-43/ FUS in motor neuron disease: Complexity and challenges. Progress in Neurobiology. Oct-Nov; 145-146:78-97. [review]

N. F. Liachko, A. Saxton, P.J. McMillan, T.J. Strovas, H.N. Currey, L.M. Taylor, J. M. Wheeler, A.L. Oblak, B. Ghetti, T.J. Montine, C.D. Keene, M. Raskind, T.D. Bird, B.C. Kraemer. 2016. The phosphatase calcineurin regulates pathological TDP-43 phosphorylation. Acta Neuropathologica. Oct; 132(4):545-61. [original work]

A. Jablonski, T. Lamitina, N. F. Liachko, M. Sabatella, J. Liu, L. Zhang, L. Ostrow, P. Gupta, C.-Y. Wu, S. Doshi, J. Mojsilovic-Petrovic, H. Lans, J. Wang, B. Kraemer, R. Kalb. 2015. Loss of RAD-23 protects against models of motor neuron disease by enhancing mutant protein clearance. J Neuroscience. Oct 21:35(42):14286-306. [original work]

N. F. Liachko, P.J. McMillan, T.J. Strovas, L. Greenup, B. Ghetti, M.A. Raskind, T.J. Montine, T.D. Bird, J.B. Leverenz, B.C. Kraemer. 2014. The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43. PLoS Genetics. Dec 4;10(12). [original work]

I.G. Salado, M. Redondo, M.L. Bello, C. Perez, N.F. Liachko, B.C. Kraemer, L. Miguel, M. Lecourtois, C. Gil, A. Martinez, D.I. Perez. 2014. Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis. J Med Chem. 57(6):2755-72. [original work]

N.F. Liachko, P.J. McMillan, C.R. Guthrie, T.D. Bird, J.B. Leverenz, B.C. Kraemer. 2013. CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration. Annals of Neurology. 74(1):39-52. [original work]

A.V. McCormick, J.M. Wheeler, C.R. Guthrie, N.F. Liachko, B.C. Kraemer. 2013. Dopamine D2 Receptor antagonism suppresses tau aggregation and neurotoxicity. Biological Psychiatry. 73(5):464-71. [original work]

N.F. Liachko, C.R. Guthrie, B.C. Kraemer. 2010. Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy. J Neuroscience. 30(48):16208-19. [original work]

N. Liachko, R. Davidowitz, S.S. Lee. 2008. Combined informatic and expression screen identifies the novel DAF-16 target HLH-13. Developmental Biology. 327(1):97-105. [original work]

X. Zhao, H. Shi, A. Sevilimedu, N. Liachko, HC Nelson, JT Lis. 2006. An RNA aptamer that interferes with the DNA binding of the HSF transcription activator. Nucleic Acids Research. 34(13):3763-3769. [original work]

C.D. Link, C.P. Tomberlin, N.F. Liachko. 2016. Cold-tolerance is a fast and easy method to identify neuronal dysfunction in C. elegans. The Worm Breeders Gazette. July 1. [original work]